Loading…
Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001
Cardiovascular disease (CVD) is the major cause of mortality in dialysis patients. Aspirin, beta‐blockers, statins, and angiotensin‐converting enzyme (ACE) inhibitors reduce CVD mortality in the general population, as may angiotensin II receptor antagonists. The prevalence of cardiovascular risk fac...
Saved in:
| Published in: | Nephrology (Carlton, Vic.) Vic.), 2003-08, Vol.8 (4), p.177-183 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4027-f4799730034c92b6c3bcd6f883176b8e1de8fc44c5dd6e1c2d3ab1b759dc428c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4027-f4799730034c92b6c3bcd6f883176b8e1de8fc44c5dd6e1c2d3ab1b759dc428c3 |
| container_end_page | 183 |
| container_issue | 4 |
| container_start_page | 177 |
| container_title | Nephrology (Carlton, Vic.) |
| container_volume | 8 |
| creator | CHOW, Fiona YF POLKINGHORNE, Kevan R CHADBAN, Steven J ATKINS, Robert C KERR, Peter G |
| description | Cardiovascular disease (CVD) is the major cause of mortality in dialysis patients. Aspirin, beta‐blockers, statins, and angiotensin‐converting enzyme (ACE) inhibitors reduce CVD mortality in the general population, as may angiotensin II receptor antagonists. The prevalence of cardiovascular risk factors and usage rates of cardioprotective agents in end‐stage renal failure are unknown. A retrospective, cross‐sectional study of dialysis patients was performed to compare: (i) prevalence of cardiovascular risk factors (age, hypertension, hyperlipidaemia, diabetes mellitus, and smoking); (ii) use of cardioprotective agents; and (iii) prevalence of cardiovascular disease between the time‐points: 1996 (n = 262) versus 2001 (n = 369). We found an increase in the risk factors of age (53.6 ± 14.9 years in 1996 vs 58.4 ± 14.3 in 2001; P |
| doi_str_mv | 10.1046/j.1440-1797.2003.00157.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71568726</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71568726</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4027-f4799730034c92b6c3bcd6f883176b8e1de8fc44c5dd6e1c2d3ab1b759dc428c3</originalsourceid><addsrcrecordid>eNqNkMFu1DAURSNERUvhF5BX7BLs2LEdxKZMy7RVKUgtYmk59ovwNJOktqed_D2eyahsWflJPvf6-WQZIrggmPFPq4IwhnMialGUGNMCY1KJYvsqO3m5eJ1mWuK8opU8zt6GsEqQKDl5kx2TCpNSEHmSTQvtrRuedDCbTnvkXXhArkfW6W4KLqBRRwd9DJ_RGTLDetSJGHo0tDPaahMHH5DuLTL7qtEPEUx0T4DiH_B6nFAD8RmgR6Su-Z5MO5N32VGruwDvD-dp9uvbxf3iMr_5sbxanN3khuFS5C0TdS1o-iQzddlwQxtjeSslJYI3EogF2RrGTGUtB2JKS3VDGlHV1rBSGnqafZx702KPGwhRrV0w0HW6h2ETlCAVl8lLAuUMGj-E4KFVo3dr7SdFsNppVyu1s6t2dtVOu9prV9sU_XB4Y9Oswf4LHjwn4MsMPLsOpv8uVrcXP9OQ4vkcdyHC9iWu_YPigopK_b5dqiU__37Nzu_UV_oX-XaggA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71568726</pqid></control><display><type>article</type><title>Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001</title><source>Wiley</source><creator>CHOW, Fiona YF ; POLKINGHORNE, Kevan R ; CHADBAN, Steven J ; ATKINS, Robert C ; KERR, Peter G</creator><creatorcontrib>CHOW, Fiona YF ; POLKINGHORNE, Kevan R ; CHADBAN, Steven J ; ATKINS, Robert C ; KERR, Peter G</creatorcontrib><description>Cardiovascular disease (CVD) is the major cause of mortality in dialysis patients. Aspirin, beta‐blockers, statins, and angiotensin‐converting enzyme (ACE) inhibitors reduce CVD mortality in the general population, as may angiotensin II receptor antagonists. The prevalence of cardiovascular risk factors and usage rates of cardioprotective agents in end‐stage renal failure are unknown. A retrospective, cross‐sectional study of dialysis patients was performed to compare: (i) prevalence of cardiovascular risk factors (age, hypertension, hyperlipidaemia, diabetes mellitus, and smoking); (ii) use of cardioprotective agents; and (iii) prevalence of cardiovascular disease between the time‐points: 1996 (n = 262) versus 2001 (n = 369). We found an increase in the risk factors of age (53.6 ± 14.9 years in 1996 vs 58.4 ± 14.3 in 2001; P < 0.001) and hyperlipidaemia (45 vs 51.8%; P < 0.001) between the two time‐points, with a reduction in the prevalence of smoking (14.5 vs 8.1%; P = 0.016). There was no difference in the prevalence of cardiovascular disease (37.4 vs 40.7%; P = 0.44). Cardioprotective agents were underutilized, with improvement in prescribing practice between 1996 and in 2001, especially in the usage of statins (21.4 vs 38.7% in 2001; P = 0.019). In conclusion, CVD is the primary cause of mortality in our dialysis patients. Although traditional cardiovascular risk factors affect the majority of the dialysis population, underutilization of cardioprotective agents is common. Proof of efficacy of these agents in this population of enormous risk is urgently required.</description><identifier>ISSN: 1320-5358</identifier><identifier>EISSN: 1440-1797</identifier><identifier>DOI: 10.1046/j.1440-1797.2003.00157.x</identifier><identifier>PMID: 15012718</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Science Pty</publisher><subject>Cardiotonic Agents - therapeutic use ; cardiovascular disease ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - prevention & control ; chronic renal failure ; Cross-Sectional Studies ; diabetes ; Female ; Humans ; hyperlipidaemia ; hypertension ; Male ; Middle Aged ; Prevalence ; Renal Dialysis - adverse effects ; Retrospective Studies ; Risk Factors ; smoking ; Survival Analysis ; Survival Rate</subject><ispartof>Nephrology (Carlton, Vic.), 2003-08, Vol.8 (4), p.177-183</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4027-f4799730034c92b6c3bcd6f883176b8e1de8fc44c5dd6e1c2d3ab1b759dc428c3</citedby><cites>FETCH-LOGICAL-c4027-f4799730034c92b6c3bcd6f883176b8e1de8fc44c5dd6e1c2d3ab1b759dc428c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15012718$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHOW, Fiona YF</creatorcontrib><creatorcontrib>POLKINGHORNE, Kevan R</creatorcontrib><creatorcontrib>CHADBAN, Steven J</creatorcontrib><creatorcontrib>ATKINS, Robert C</creatorcontrib><creatorcontrib>KERR, Peter G</creatorcontrib><title>Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001</title><title>Nephrology (Carlton, Vic.)</title><addtitle>Nephrology (Carlton)</addtitle><description>Cardiovascular disease (CVD) is the major cause of mortality in dialysis patients. Aspirin, beta‐blockers, statins, and angiotensin‐converting enzyme (ACE) inhibitors reduce CVD mortality in the general population, as may angiotensin II receptor antagonists. The prevalence of cardiovascular risk factors and usage rates of cardioprotective agents in end‐stage renal failure are unknown. A retrospective, cross‐sectional study of dialysis patients was performed to compare: (i) prevalence of cardiovascular risk factors (age, hypertension, hyperlipidaemia, diabetes mellitus, and smoking); (ii) use of cardioprotective agents; and (iii) prevalence of cardiovascular disease between the time‐points: 1996 (n = 262) versus 2001 (n = 369). We found an increase in the risk factors of age (53.6 ± 14.9 years in 1996 vs 58.4 ± 14.3 in 2001; P < 0.001) and hyperlipidaemia (45 vs 51.8%; P < 0.001) between the two time‐points, with a reduction in the prevalence of smoking (14.5 vs 8.1%; P = 0.016). There was no difference in the prevalence of cardiovascular disease (37.4 vs 40.7%; P = 0.44). Cardioprotective agents were underutilized, with improvement in prescribing practice between 1996 and in 2001, especially in the usage of statins (21.4 vs 38.7% in 2001; P = 0.019). In conclusion, CVD is the primary cause of mortality in our dialysis patients. Although traditional cardiovascular risk factors affect the majority of the dialysis population, underutilization of cardioprotective agents is common. Proof of efficacy of these agents in this population of enormous risk is urgently required.</description><subject>Cardiotonic Agents - therapeutic use</subject><subject>cardiovascular disease</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>chronic renal failure</subject><subject>Cross-Sectional Studies</subject><subject>diabetes</subject><subject>Female</subject><subject>Humans</subject><subject>hyperlipidaemia</subject><subject>hypertension</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prevalence</subject><subject>Renal Dialysis - adverse effects</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>smoking</subject><subject>Survival Analysis</subject><subject>Survival Rate</subject><issn>1320-5358</issn><issn>1440-1797</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqNkMFu1DAURSNERUvhF5BX7BLs2LEdxKZMy7RVKUgtYmk59ovwNJOktqed_D2eyahsWflJPvf6-WQZIrggmPFPq4IwhnMialGUGNMCY1KJYvsqO3m5eJ1mWuK8opU8zt6GsEqQKDl5kx2TCpNSEHmSTQvtrRuedDCbTnvkXXhArkfW6W4KLqBRRwd9DJ_RGTLDetSJGHo0tDPaahMHH5DuLTL7qtEPEUx0T4DiH_B6nFAD8RmgR6Su-Z5MO5N32VGruwDvD-dp9uvbxf3iMr_5sbxanN3khuFS5C0TdS1o-iQzddlwQxtjeSslJYI3EogF2RrGTGUtB2JKS3VDGlHV1rBSGnqafZx702KPGwhRrV0w0HW6h2ETlCAVl8lLAuUMGj-E4KFVo3dr7SdFsNppVyu1s6t2dtVOu9prV9sU_XB4Y9Oswf4LHjwn4MsMPLsOpv8uVrcXP9OQ4vkcdyHC9iWu_YPigopK_b5dqiU__37Nzu_UV_oX-XaggA</recordid><startdate>200308</startdate><enddate>200308</enddate><creator>CHOW, Fiona YF</creator><creator>POLKINGHORNE, Kevan R</creator><creator>CHADBAN, Steven J</creator><creator>ATKINS, Robert C</creator><creator>KERR, Peter G</creator><general>Blackwell Science Pty</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200308</creationdate><title>Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001</title><author>CHOW, Fiona YF ; POLKINGHORNE, Kevan R ; CHADBAN, Steven J ; ATKINS, Robert C ; KERR, Peter G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4027-f4799730034c92b6c3bcd6f883176b8e1de8fc44c5dd6e1c2d3ab1b759dc428c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Cardiotonic Agents - therapeutic use</topic><topic>cardiovascular disease</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>chronic renal failure</topic><topic>Cross-Sectional Studies</topic><topic>diabetes</topic><topic>Female</topic><topic>Humans</topic><topic>hyperlipidaemia</topic><topic>hypertension</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prevalence</topic><topic>Renal Dialysis - adverse effects</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>smoking</topic><topic>Survival Analysis</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHOW, Fiona YF</creatorcontrib><creatorcontrib>POLKINGHORNE, Kevan R</creatorcontrib><creatorcontrib>CHADBAN, Steven J</creatorcontrib><creatorcontrib>ATKINS, Robert C</creatorcontrib><creatorcontrib>KERR, Peter G</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nephrology (Carlton, Vic.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHOW, Fiona YF</au><au>POLKINGHORNE, Kevan R</au><au>CHADBAN, Steven J</au><au>ATKINS, Robert C</au><au>KERR, Peter G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001</atitle><jtitle>Nephrology (Carlton, Vic.)</jtitle><addtitle>Nephrology (Carlton)</addtitle><date>2003-08</date><risdate>2003</risdate><volume>8</volume><issue>4</issue><spage>177</spage><epage>183</epage><pages>177-183</pages><issn>1320-5358</issn><eissn>1440-1797</eissn><abstract>Cardiovascular disease (CVD) is the major cause of mortality in dialysis patients. Aspirin, beta‐blockers, statins, and angiotensin‐converting enzyme (ACE) inhibitors reduce CVD mortality in the general population, as may angiotensin II receptor antagonists. The prevalence of cardiovascular risk factors and usage rates of cardioprotective agents in end‐stage renal failure are unknown. A retrospective, cross‐sectional study of dialysis patients was performed to compare: (i) prevalence of cardiovascular risk factors (age, hypertension, hyperlipidaemia, diabetes mellitus, and smoking); (ii) use of cardioprotective agents; and (iii) prevalence of cardiovascular disease between the time‐points: 1996 (n = 262) versus 2001 (n = 369). We found an increase in the risk factors of age (53.6 ± 14.9 years in 1996 vs 58.4 ± 14.3 in 2001; P < 0.001) and hyperlipidaemia (45 vs 51.8%; P < 0.001) between the two time‐points, with a reduction in the prevalence of smoking (14.5 vs 8.1%; P = 0.016). There was no difference in the prevalence of cardiovascular disease (37.4 vs 40.7%; P = 0.44). Cardioprotective agents were underutilized, with improvement in prescribing practice between 1996 and in 2001, especially in the usage of statins (21.4 vs 38.7% in 2001; P = 0.019). In conclusion, CVD is the primary cause of mortality in our dialysis patients. Although traditional cardiovascular risk factors affect the majority of the dialysis population, underutilization of cardioprotective agents is common. Proof of efficacy of these agents in this population of enormous risk is urgently required.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Science Pty</pub><pmid>15012718</pmid><doi>10.1046/j.1440-1797.2003.00157.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1320-5358 |
| ispartof | Nephrology (Carlton, Vic.), 2003-08, Vol.8 (4), p.177-183 |
| issn | 1320-5358 1440-1797 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71568726 |
| source | Wiley |
| subjects | Cardiotonic Agents - therapeutic use cardiovascular disease Cardiovascular Diseases - epidemiology Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control chronic renal failure Cross-Sectional Studies diabetes Female Humans hyperlipidaemia hypertension Male Middle Aged Prevalence Renal Dialysis - adverse effects Retrospective Studies Risk Factors smoking Survival Analysis Survival Rate |
| title | Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T22%3A07%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiovascular%20risk%20in%20dialysis%20patients:%20A%20comparison%20of%20risk%20factors%20and%20cardioprotective%20therapy%20between%201996%20and%202001&rft.jtitle=Nephrology%20(Carlton,%20Vic.)&rft.au=CHOW,%20Fiona%20YF&rft.date=2003-08&rft.volume=8&rft.issue=4&rft.spage=177&rft.epage=183&rft.pages=177-183&rft.issn=1320-5358&rft.eissn=1440-1797&rft_id=info:doi/10.1046/j.1440-1797.2003.00157.x&rft_dat=%3Cproquest_cross%3E71568726%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4027-f4799730034c92b6c3bcd6f883176b8e1de8fc44c5dd6e1c2d3ab1b759dc428c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71568726&rft_id=info:pmid/15012718&rfr_iscdi=true |